Longeveron Logo.jpg
Longeveron to Present at Biotech Showcase 2025
18. Dezember 2024 09:10 ET | Longeveron
Longeveron Chief Executive Officer Wa’el Hashad will give a corporate presentation at Biotech Showcase, being held January 13-15, 2025.
Vaccinex logo
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
17. Dezember 2024 09:00 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
Global Alzheimer’s P
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration with Eli Lilly and Company for the Transformative Bio-Hermes-002 Study
09. Dezember 2024 10:00 ET | Global Alzheimer’s Platform Foundation®
Washington D.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Eli Lilly and Company (Lilly) to the Bio-Hermes-002 study. This...
Longeveron Logo.jpg
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
02. Dezember 2024 09:05 ET | Longeveron
Longeveron will participate in the Emerging Growth Virtual Conference with company presentation December 5th at 12:00pm ET.
ANVS logo.jpg
Annovis to Host Year-End Investor Webcast on December 11, 2024
25. November 2024 08:00 ET | Annovis Bio, Inc.
MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased...
Wa'el Hashad
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update
12. November 2024 16:05 ET | Longeveron
Longeveron reports 3Q24 financial results. Pivotal Phase 2b clinical trial in HLHS achieves 80% enrollment. Positive Phase 2 data for Alzheimer's disease.
Bridging Health Equi
Bridging Health Equity Gaps: Creyos Launches an Even More Accessible Patient Experience
05. November 2024 08:00 ET | Creyos
Toronto, Canada, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Creyos, a leader in cognitive and behavioral health assessment, has announced significant enhancements to its online platform to improve...
Joshua Hare
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
29. Oktober 2024 10:00 ET | Longeveron
Longeveron presents clinical data for stem cell therapy in Alzheimer's disease. Findings offer potential mechanistic and clinical insights.
Praxis_logo 2022 copy.png
Praxis Bioresearch Obtains FDA Clearance On the IND Application for Its Lead Candidate PRX-P4-003 In Alzheimer’s Disease Apathy
29. Oktober 2024 07:48 ET | Praxis Bioresearch, Inc.
LOS ANGELES, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for...
Collaborative effort
Collaborative effort to conduct a study aimed at improving the diagnosis of Alzheimer’s and related dementias for everyone
28. Oktober 2024 10:00 ET | Global Alzheimer’s Platform Foundation®
Washington D.C., Oct. 28, 2024 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome the initial strategic partners in the Bio-Hermes-002 study. These...